AstraZeneca's Imfinzi monotherapy and the combination of Imfinzi and tremelimumab has failed to improve OS rate compared to SoC chemotherapy in head and ...
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2RPxroT
AstraZeneca's Imfinzi monotherapy and the combination of Imfinzi and tremelimumab has failed to improve OS rate compared to SoC chemotherapy in head and ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.